19 March 2019 | News
Rosenzweig brings nearly 20 years of executive financial management experience, most recently serving as chief financial officer of Entera Bio since May 2014
Check-Cap, an Israel based clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free capsule based screening method for the prevention of colorectal cancer through the detection of precancerous polyps has announced the appointment of Mira Rosenzweig as chief financial officer effective as of April 28, 2019.
Rosenzweig brings nearly 20 years of executive financial management experience, most recently serving as chief financial officer of Entera Bio since May 2014.
Alex Ovadia, chief executive officer of Check-Cap, stated, "We are pleased to welcome Mira to Check-Cap. This is an exciting time for our team as we advance C-Scan® toward U.S clinical trials and prepare for commercialization in the E.U. and Israel. We believe Mira's substantial experience in financial management within life sciences and commercial stage companies will prove invaluable as we continue to efficiently execute our business plan."
"Check-Cap's C-Scan® has the potential to fundamentally redefine colon cancer screening through precancerous polyp detection. I am excited to join the company at this pivotal stage, and I look forward to working with Alex and the team to contribute to the successful launching of this novel technology”, commented Rosenzweig
Prior to Entera Bio, Rosenzweig served in various finance roles including vice president and chief financial officer of Camtek Ltd. and director of finance at Elron Electronic Industries Ltd.
Rosenzweig began her career as a senior accountant at Luboshitz Kasierer, which is now part of Ernst & Young. She holds a Bachelor of Arts in Accounting and Economics from the University of Haifa, Israel, and is a certified public accountant (Israel).